Zobrazeno 1 - 10
of 182
pro vyhledávání: '"M, Lambermont"'
Publikováno v:
Vox sanguinis. 107(3)
Background and Objectives TACSI whole blood system is designed to combine primary and secondary processing of six whole blood bags into plasma units, buffy coat and red blood cell concentrates. The aim of this study was to investigate the specificati
Autor:
G. Stockhammer, J. Brotchi, R. Leblanc, M. Bernstein, G. Schackert, F. Weber, C. Ostertag, N. H. Mulder, H. Mellstedt, R. Seiler, Y. Yonekawa, K. Twerdy, H. Kostron, O. De Witte, M. Lambermont, T. Velu, P. Laneuville, J.-G. Villemure, J. T. Rutka, P. Warnke, M. Laseur, J. J. A. Mooij, J. Boëthius, L. Mariani, M. Meyer, C. Brändli, K. Frei, D. Könu, A. Gianella-Borradori
Publikováno v:
Journal of Molecular Medicine. 75:300-304
Autor:
P, Van der Linden, M, Lambermont, A, Dierick, R, Hübner, Y, Benoit, D, De Backer, R, De Paep, A, Ferrant, D, Latinne, L, Muylle, D, Selleslag, B, Szabo, I, Thomas, B, Vandekerckhove, V, Deneys
Publikováno v:
Acta clinica Belgica. 67(3)
The following recommendations, which aim at improving the clinical diagnosis ofTRALI and the laboratory investigations that can support it, were drawn up by a working group of the Superior Health Council. TRALI is a complication of blood transfusion
Autor:
Claire Farber, M Vekemans, W W Feremans, Corinne Liesnard, M Lambermont, J. P. Van Vooren, A Kentos
Publikováno v:
Bone Marrow Transplantation. 29:273-275
The epidemiology and clinical outcome of multiple myeloma in human immunodeficiency virus (HIV)-positive patients is poorly documented. There are uncertainties concerning the optimal management of this rare disorder. We report on the use of myeloabla
Publikováno v:
Revue medicale de Bruxelles. 28(5)
Extracorporeal photochemotherapy is an immunomodulatory treatment wich is carried out in three steps: first leukapheresis, then ex vivo PUVA treatment and finally autologous transfusion. Its current "evidence-based" indications are erythrodermic cuta
Publikováno v:
Transfusion Clinique et Biologique. 20:274-275
Autor:
M, Goldman, M, Andrien, J P, Delville, E, Dupont, A, Kornreich, M, Lambermont, A, Ocmant, L, Schandené, F, Mascart, O, Pradier, P, Stordeur, M, Toungouz, W, Wijns
Publikováno v:
Revue medicale de Bruxelles. 23
New immunotherapies derived from biotechnology offer fascinating perspectives in different fields of medicine including anti-infectious vaccines, cancer, organ transplantation and autoimmune diseases. In this paper, we illustrate how the Department o
Autor:
M, Toungouz, M, Lambermont, T, Velu, C, Buelens, N, Vanderheyde, E, Bartholomé, F, Willems, D, Gangji, M, Goldman
Publikováno v:
Journal de la Societe de biologie. 195(1)
In cancer immunotherapy, the use of dendritic cells (DC) loaded with tumor-associated antigens (TAA) emerged as a promising strategy. We initiated 3 pilot clinical trials with immunological endpoints using TAA loaded autologous DC. These trials showe
Autor:
M, Toungouz, M, Libin, F, Bulté, L, Faid, F, Lehmann, D, Duriau, M, Laporte, D, Gangji, C, Bruyns, M, Lambermont, M, Goldman, T, Velu
Publikováno v:
Journal of leukocyte biology. 69(6)
Assessment of T-cell activation is pivotal for evaluation of cancer immunotherapy. We initiated a clinical trial in patients with MAGE-A1 and/or -A3 tumors using autologous DC pulsed with MAGE peptides aimed at analyzing T-cell-derived, IFN-gamma sec